The DOI matches its Crossref record; 100 of the 100 references it cites were found in a registry or an index.
Antidepressant Discontinuation Syndromes: Clinical Relevance, Prevention and Management
Abstract
Discontinuation symptoms are recognised with tricyclic antidepressants, monoamine oxidase inhibitors, selective serotonin reuptake inhibitors (SSRIs) and miscellaneous antidepressants. A wide variety of symptoms have been described, differing somewhat between antidepressant classes, and several symptom clusters or discontinuation syndromes appear to exist. A common feature is onset within a few days of stopping the antidepressant or, less commonly, reducing the dosage. Discontinuation syndromes are clinically relevant as they are common, can cause significant morbidity, can be misdiagnosed leading to inappropriate treatment and can adversely effect future antidepressant compliance. Preventative strategies include tapering antidepressants prior to stoppage and educating patients and healthcare professionals to ensure that antidepressants are taken consistently and not stopped abruptly. Most reactions are mild and short-lived and require no treatment other than patient reassurance. Severe cases can be treated symptomatically or the antidepressant can be reinstated before being gradually withdrawn. Reinstatement usually leads to symptom resolution within 24 hours. Some individuals require very conservative tapering schedules to prevent the re-emergence of symptoms. With SSRIs and venlafaxine another strategy to consider is switching to fluoxetine, which may suppress the discontinuation symptoms, but which has little tendency to cause such symptoms itself. Neonatal discontinuation symptoms can follow maternal use of antidepressants during pregnancy and possibly breast feeding. The patient and doctor must take this into consideration when making prescribing decisions. Discontinuation symptoms have received little systematic study with the result that most of the recommendations made here are based on anecdotal data or expert opinion. Research is needed to provide a firm evidence base for future recommendations.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In addition, it has been suggested that gradual discontinuation can reduce both rebound insomnia [84, 85] and rebound anxiety [1].”
From Acute and Persistent Withdrawal Syndromes Following Discontinuation of Psychotropic Medications (2020) · cites this paper as [84]
In the citing paper
“It is now suspected that antidepressant withdrawal syndrome is more common and severe than earlier presumed, affecting roughly 30–50% of those who attempt to stop their treatment.12,13,23,24”
From Protracted withdrawal syndrome after stopping antidepressants: a descriptive quantitative analysis of consumer narratives from a large internet forum (2020) · cites this paper as [24]
In the citing paper
“With new-generation antidepressants, it has been widely observed that risk of withdrawal emerges after the drugs have been taken for 1 to 2 months.24,39”
From Protracted withdrawal syndrome after stopping antidepressants: a descriptive quantitative analysis of consumer narratives from a large internet forum (2020) · cites this paper as [24]
In the citing paper
“We now have increasing evidence for postwithdrawal disorders with SSRI long-term use [6,15,16,26,37] .”
From New Classification of Selective Serotonin Reuptake Inhibitor Withdrawal (2015) · cites this paper as [15]
In the citing paper
“Persistent postwithdrawal disorders have been described with different classes of CNS drugs (e.g.protracted insomnia for alcohol and benzodiazepine withdrawal [10,36] and major depression/dysphoria for cocaine and amphetamine withdrawal [10,23] ), and even more so with specific drugs (e.g.quetiapine and paroxetine) within a drug class [6,15,16,33] .”
From New Classification of Selective Serotonin Reuptake Inhibitor Withdrawal (2015) · cites this paper as [15]
In the citing paper
“Data from controlled trials [15,20,29] , case reports [16] , and online patient reports [26] show that paroxetine is most likely to be associated with new withdrawal symptoms, and fluoxetine the least.”
From New Classification of Selective Serotonin Reuptake Inhibitor Withdrawal (2015) · cites this paper as [15]
In the citing paper
“Rebound anxiety [2,14] and rebound panic [15] were then reported with abrupt benzodiazepine discontinuation [9] .”
From New Classification of Selective Serotonin Reuptake Inhibitor Withdrawal (2015) · cites this paper as [15]
In the citing paper
“According to most studies [1,15,16,20,29] , even with gradual tapering, withdrawal symptoms still occur.”
From New Classification of Selective Serotonin Reuptake Inhibitor Withdrawal (2015) · cites this paper as [15]
In the citing paper
“They may resemble rebound symptoms being more severe than the original symptoms, but these disorders persist at least 6 weeks in contrast to rebound symptoms and [6,15,16,26,37] .”
From New Classification of Selective Serotonin Reuptake Inhibitor Withdrawal (2015) · cites this paper as [15]
In the citing paper
“Given the evidence for the high risk of disabling withdrawal with paroxetine”
From New Classification of Selective Serotonin Reuptake Inhibitor Withdrawal (2015) · cites this paper as [15]
In the citing paper
“thought to be related to noradrenergic and cholinergic supersensitivity [15,35]”
From New Classification of Selective Serotonin Reuptake Inhibitor Withdrawal (2015) · cites this paper as [15]
In the citing paper
“Persistent postwithdrawal panic disorder [15,38] has been shown to occur following withdrawal of paroxetine, and paroxetine has also been associated with other postwithdrawal disorders [6,15,16] .”
From New Classification of Selective Serotonin Reuptake Inhibitor Withdrawal (2015) · cites this paper as [15]
Citations
Cites
Birth Outcomes in Pregnant Women Taking Fluoxetine
Chambers, C., Johnson, K. A., Dick, L. M., Felix, R. J., & Jones, K. L. (1996) · New England Journal of Medicine · doi:10.1056/nejm199610033351402 · Cited by 735
Selective serotonin reuptake inhibitor discontinuation syndrome: a randomized clinical trial
Rosenbaum, J. F., Fava, M., Hoog, S. L., Ascroft, R. C., & Krebs, W. B. (1998) · Biological Psychiatry · doi:10.1016/s0006-3223(98)00126-7 · Cited by 574
Priest, R. G., Vize, C., Roberts, A., Roberts, M., & Tylee, A. (1996) · BMJ · doi:10.1136/bmj.313.7061.858 · Cited by 385
Serotonin Reuptake Inhibitor Withdrawal
Coupland, N. J., Bell, C. J., & Potokar, J. P. (1996) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199610000-00003 · Cited by 303
(1993) · American Journal of Psychiatry · doi:10.1176/ajp.150.10.1485 · Cited by 263
Paroxetine in the Treatment of Panic Disorder a Randomised, Double-Blind, Placebo-Controlled Study
Oehrberg, S., Christiansen, P. E., Behnke, K., Borup, A. L., Severin, B., Soegaard, J., Calberg, H., Judge, R., Ohrstrom, J. K., & Manniche, P. M. (1995) · British Journal of Psychiatry · doi:10.1192/bjp.167.3.374 · Cited by 261
Pharmacologic Treatment of Depression During Pregnancy
Wisner, K. L. (1999) · JAMA · doi:10.1001/jama.282.13.1264 · Cited by 250
Emergence of Adverse Events Following Discontinuation of Treatment With Extended-Release Venlafaxine
D, M. F. M., Mulroy, R., Alpert, J. E., Nierenberg, A. A., & Rosenbaum, J. F. (1997) · American Journal of Psychiatry · doi:10.1176/ajp.154.12.1760 · Cited by 198
Withdrawal syndromes associated with antipsychotic drugs
Gárdos, G., Jo, C., & Tarsy, D. (1978) · American Journal of Psychiatry · doi:10.1176/ajp.135.11.1321 · Cited by 192
Michelson, D., Fava, M., Amsterdam, J., Apter, J., Londborg, P., Tamura, R., & Tepner, R. G. (2000) · British Journal of Psychiatry · doi:10.1192/bjp.176.4.363 · Cited by 181
Research works printed but not linked: 25
- Ceccherini-Nelli, 1993, Am J Psychiatry, 150, 165
- Diamond, 1989, Psychopharmacol Bull, 25, 209
- Law, 1981, Am J Psychiatry, 118, 647
- Geller, 1987, J Clin Psychopharmacol, 7, 252
- Liskin, 1984, J Clin Psychopharmacol, 5, 46
- Halle, 1993, J Psychiatry Neurosci, 18, 49
- Einbinder, 1995, Am J Psychiatry, 152, 1253
- Black, 1993, J Clin Psychiatry, 54, 146
- Louie, 1996, Am J Psychiatry, 153, 1652
- Schatzberg, 1997, J Clin Psychiatry, 58, 5
- DArcy, 1993, Int Pharm J, 7, 140
- Stoukides, 1991, Am J Psychiatry, 148, 1263
- Kasantikul, 1995, J Med Assoc Thai, 78, 53
- Parker, 1998, Aust N Z J Psychiatry, 32, 292
- Agelink, 1997, Am J Psychiatry, 154, 1473
- Wolfe, 1997, Am Fam Physician, 56, 452
- 1996, Aust Adverse Drug Reactions Bull Nov, 15, 3
- Frost, 1995, Am J Psychiatry, 152, 810
- Stem, 1980, J Clin Psychiat, 41, 66
- Mander, 1998, Lancet, 339, 15
- Rosenblatt, 1996, Curr Affect Illness, 15, 8
- Phillips, 1995, Am J Psychiatry, 152, 645
- Eggermont, 1972, Acta Paediatr Belg, 26, 197
- 1997, Austral Adverse Drug Reactions Bull Nov, 16, 14
- Dahl, 1997, Br J Psychiatry, 171, 91
Cited by
Sorted by citations
Adverse Effects of Atypical Antipsychotics
Haddad, P. M., & Sharma, S. G. (2007) · CNS Drugs · doi:10.2165/00023210-200721110-00004 · Cited by 468
Self-citationDavies, J., & Read, J. (2019) · Addictive Behaviors · doi:10.1016/j.addbeh.2018.08.027 · Cited by 387
Walter, H. J., Bukstein, O. G., Abright, A. R., Keable, H., Ramtekkar, U., Ripperger-Suhler, J., & Rockhill, C. (2020) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1016/j.jaac.2020.05.005 · Cited by 335
Efficacy and Tolerability of Desvenlafaxine Succinate Treatment for Menopausal Vasomotor Symptoms
Speroff, L., Gass, M. L. S., Constantine, G. D., & Olivier, S. (2008) · Obstetrics and Gynecology · doi:10.1097/01.aog.0000297371.89129.b3 · Cited by 333
Maternal Selective Serotonin Reuptake Inhibitor Use During Pregnancy and Newborn Neurobehavior
Zeskind, P. S., & Stephens, L. E. (2004) · PEDIATRICS · doi:10.1542/peds.113.2.368 · Cited by 279
Acute and Persistent Withdrawal Syndromes Following Discontinuation of Psychotropic Medications
Cosci, F., & Chouinard, G. (2020) · Psychotherapy and Psychosomatics · doi:10.1159/000506868 · Cited by 265
Current diagnosis and treatment of anxiety disorders.
Bystritsky, A., Khalsa, S. S., Cameron, M., & Schiffman, J. E. (2013) · Europe PMC (PubMed Central) · Cited by 249
Neurological complications of psychiatric drugs: clinical features and management
Haddad, P. M., & Dursun, S. M. (2007) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.918 · Cited by 219
Self-citationWalter, H. J., Abright, A. R., Bukstein, O. G., Diamond, J., Keable, H., Ripperger-Suhler, J. A., & Rockhill, C. (2022) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1016/j.jaac.2022.10.001 · Cited by 221
Bauer, M., Severus, E., Köhler, S., Whybrow, P. C., Angst, J., Möller, H.-J., & on behalf of the Wfsbp Task Force on Treatment Guidelines for Unipolar Depressive Disorders (2015) · The World Journal of Biological Psychiatry · doi:10.3109/15622975.2014.1001786 · Cited by 199
Rendleman, R. L., & Walkup, J. T. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4377-0435-8.00049-4 · Cited by 197
Sleep disruption in critically ill patients – pharmacological considerations
Bourne, R. S., & MILLS, G. H. (2004) · Anaesthesia · doi:10.1111/j.1365-2044.2004.03664.x · Cited by 192
Lattimore, K. A., Donn, S. M., Kaciroti, N., Kemper, A. R., Neal, C. R., & Vazquez, D. M. (2005) · Journal of Perinatology · doi:10.1038/sj.jp.7211352 · Cited by 189
Sleep in the intensive care unit
Drouot, X., Cabello, B., d’Ortho, M., & Brochard, L. J. (2008) · Sleep Medicine Reviews · doi:10.1016/j.smrv.2007.11.004 · Cited by 167
New Classification of Selective Serotonin Reuptake Inhibitor Withdrawal
Chouinard, G., & Chouinard, V.-A. (2015) · Psychotherapy and Psychosomatics · doi:10.1159/000371865 · Cited by 164
Bauer, M., Whybrow, P. C., Angst, J., Versiani, M., Möller, H., & WFSBP Task Force on Treatment Guide (2002) · The World Journal of Biological Psychiatry · doi:10.3109/15622970209150605 · Cited by 159
An adaptationist perspective on the etiology of depression
Durisko, Z., Mulsant, B. H., & Andrews, P. W. (2015) · Journal of Affective Disorders · doi:10.1016/j.jad.2014.09.032 · Cited by 140
Discontinuation symptoms in depression and anxiety disorders
Baldwin, D. S., Montgomery, S. A., Nil, R., & Lader, M. (2007) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145705006358 · Cited by 140
Prevention of relapse in generalized anxiety disorder by escitalopram treatment
Allgulander, C., Florea, I., & Huusom, A. K. T. (2005) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145705005973 · Cited by 130
Illness risk following rapid versus gradual discontinuation of antidepressants
Baldessarini, R. J., Tondo, L., Ghiani, C., & Lepri, B. (2010) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2010.09060880 · Cited by 123
Jacobsen, J. P. R., Krystal, A. D., Krishnan, K. R. R., & Caron, M. G. (2016) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2016.09.001 · Cited by 120
Hudson, J. I., Wohlreich, M. M., Kajdasz, D. K., Mallinckrodt, C. H., Watkin, J. G., & Martynov, O. V. (2005) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.696 · Cited by 116
Oberlander, T. F., Bonaguro, R. J., Misri, S. K., Papsdorf, M., Ross, C. J., & Simpson, E. M. (2007) · Molecular Psychiatry · doi:10.1038/sj.mp.4002007 · Cited by 113
Antidepressant-Induced Activation in Children and Adolescents: Risk, Recognition and Management
Luft, M. J., Lamy, M., DelBello, M. P., McNamara, R. K., & Strawn, J. R. (2018) · Current problems in pediatric and adolescent health care · doi:10.1016/j.cppeds.2017.12.001 · Cited by 127
Nielsen, M., Hansen, E. H., & Gøtzsche, P. C. (2012) · Addiction · doi:10.1111/j.1360-0443.2011.03686.x · Cited by 103
Discontinuation of Antidepressant Medication Among Latinos in the USA
Hodgkin, D., Volpe-Vartanian, J., & Alegria, M. M. (2007) · The Journal of Behavioral Health Services & Research · doi:10.1007/s11414-007-9070-6 · Cited by 101
Safety of Selective Serotonin Reuptake Inhibitors in Pregnancy
Alwan, S. S., & Friedman, J. M. (2009) · CNS Drugs · doi:10.2165/00023210-200923060-00004 · Cited by 103
The use of psychotropic medication during pregnancy: how about the newborn?
Kieviet, N., Honig, & Dolman (2013) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s36394 · Cited by 100
Gutierrez, M. A., Stimmel, G. L., & Aiso, J. Y. (2003) · Clinical Therapeutics · doi:10.1016/s0149-2918(03)80210-2 · Cited by 101
Archer, D. F., Seidman, L. S., Constantine, G. D., Pickar, J. H., & Olivier, S. (2008) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2008.09.877 · Cited by 96
Pharmacological treatment of generalized anxiety disorder
Reinhold, J. A., Mandos, L. A., Rickels, K., & Lohoff, F. W. (2011) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2011.618496 · Cited by 90
Lerner, A., & Klein, M. (2019) · Brain Communications · doi:10.1093/braincomms/fcz025 · Cited by 89
David, P., Kajdasz, D. K., Desaiah, D., & Haddad, P. M. (2005) · Journal of Affective Disorders · doi:10.1016/j.jad.2005.09.003 · Cited by 86
Self-citationBogetto, F., Bellino, S., Revello, R. B., & Patria, L. (2002) · CNS Drugs · doi:10.2165/00023210-200216040-00006 · Cited by 80
Overuse of Antidepressant Drugs for the Treatment of Depression
Jureidini, J. N., & Tonkin, A. (2006) · CNS Drugs · doi:10.2165/00023210-200620080-00002 · Cited by 81
Pharmacotherapy of Mood Disorders
Thase, M. E., & Denko, T. (2008) · Annual Review of Clinical Psychology · doi:10.1146/annurev.clinpsy.2.022305.095301 · Cited by 82
Schatzberg, A. F., Blier, P., Delgado, P. L., D, M. F. M., Haddad, P. M., & Shelton, R. C. (2006) · PubMed · Cited by 78
Self-citationUse of psychopharmacological agents for functional gastrointestinal disorders.
Clouse, R. E., & Lustman, P. J. (2005) · Gut · doi:10.1136/gut.2004.048884 · Cited by 76
Hengartner, M. P., Schulthess, L., Sorensen, A., & Framer, A. (2020) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125320980573 · Cited by 74
Framer, A. (2021) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125321991274 · Cited by 73
van Geffen, E. C. G., Hugtenburg, J. G., Heerdink, E. R., van Hulten, R. P., & Egberts, A. C. G. (2005) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-005-0921-x · Cited by 72
The pharmacological management of depression
Kupfer, D. J. (2005) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2005.7.3/dkupfer · Cited by 69
Antidepressants: update on new agents and indications.
Ables, A. Z., & Baughman, O. L. (2003) · PubMed · Cited by 67
Gastaldon, C., Schoretsanitis, G., Arzenton, E., Raschi, E., Papola, D., Ostuzzi, G., Moretti, U., Seifritz, E., Kane, J. M., Trifirò, G., et al. (2022) · Drug Safety · doi:10.1007/s40264-022-01246-4 · Cited by 68
Patients' experiences of medication for anxiety and depression: Effects on working life
Haslam, C. (2004) · Family Practice · doi:10.1093/fampra/cmh218 · Cited by 63
Depression and Erectile Dysfunction
Makhlouf, A. A., Kparker, A., & NIEDERBERGER, C. S. (2007) · Urologic Clinics of North America · doi:10.1016/j.ucl.2007.08.009 · Cited by 65
Kruger, J., Conway, T., Kaneene, J., Perry, R. L., Hagenlocker, E., Golombek, A., & Stuhler, J. (2003) · Journal of the American Veterinary Medical Association · doi:10.2460/javma.2003.222.749 · Cited by 64
Medication adherence: Pharmacist perspective
Bubalo, J. S., Clark, R. K., Jiing, S., Johnson, N. B., Miller, K. A., Shipman, C. J., & Sweet, A. L. (2010) · Journal of the American Pharmacists Association · doi:10.1331/japha.2010.08180 · Cited by 60
New insights on the antidepressant discontinuation syndrome
Harvey, B. H., & Slabbert, F. N. (2014) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.2429 · Cited by 62
LADER, M. H. (2007) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2007.05.004 · Cited by 61
Painful Physical Symptoms in Depression: A Clinical Challenge
Wise, T. N., Fishbain, D. A., & Holder‐Perkins, V. (2007) · Pain Medicine · doi:10.1111/j.1526-4637.2007.00352.x · Cited by 55
Drug-Induced Insomnia and Excessive Sleepiness
Gastel, A. V. (2018) · Sleep Medicine Clinics · doi:10.1016/j.jsmc.2018.02.001 · Cited by 55
Safety and side effect profile of fluoxetine
Wernicke, J. (2004) · Expert Opinion on Drug Safety · doi:10.1517/14740338.3.5.495 · Cited by 52
Haddad, P. M., Pal, B. R., Clarke, P., Wieck, A., & Sridhiran, S. (2005) · Journal of Psychopharmacology · doi:10.1177/0269881105056554 · Cited by 51
Self-citationThe Marketization of Depression: The Prescribing of SSRI Antidepressants to Women *
Currie, J. (2005) · Cited by 49
Antidepressant withdrawal – the tide is finally turning
Hengartner, M. P., Davies, J., & Read, J. (2020) · Epidemiology and Psychiatric Sciences · doi:10.1017/s2045796019000465 · Cited by 48
Vestibular symptoms and history taking
Bisdorff, A. R. (2016) · Handbook of clinical neurology · doi:10.1016/b978-0-444-63437-5.00006-6 · Cited by 48
Usami, M., Iwadare, Y., Kodaira, M., Watanabe, K., & Saito, K. (2014) · PLoS ONE · doi:10.1371/journal.pone.0086290 · Cited by 43
Boucher, N., Koren, G., & Beaulac-Baillargeon, L. (2009) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0b013e3181a58fb4 · Cited by 42
Closing the Deal: A Cross-Cultural Comparison of Treatment Resistance
Bergen, C., Stivers, T., Barnes, R., Heritage, J. C., McCabe, R., Thompson, L. R., & Toerien, M. (2017) · Health Communication · doi:10.1080/10410236.2017.1350917 · Cited by 44
Lacasse, J. R., & Cacciatore, J. (2014) · Death Studies · doi:10.1080/07481187.2013.820229 · Cited by 44
Gruber, S., Whitworth, A. B., Kemmler, G., & Papp, C. (2010) · Journal of Plastic Reconstructive & Aesthetic Surgery · doi:10.1016/j.bjps.2010.03.032 · Cited by 39
Antidepressants, suicidality and rebound effect: evidence of similitude?
Teixeira, M. Z. (2009) · Homeopathy · doi:10.1016/j.homp.2009.02.004 · Cited by 39
Empirically supported use of psychiatric medications in adolescents and adults with IBD
Thorkelson, G., Bielefeldt, K., & Szigethy, E. (2016) · Inflammatory Bowel Diseases · doi:10.1097/mib.0000000000000734 · Cited by 39
Antidepressant Discontinuation Syndrome
Antai-Otong, D. (2003) · Perspectives In Psychiatric Care · doi:10.1111/j.1744-6163.2003.00127.x · Cited by 38
Pharmacological Aspects of Neonatal Antidepressant Withdrawal
ter Horst, P. G. J., Jansman, F. G. A., van Lingen, R. A., Smit, J. P., den Berg, L. T. W. D. J., & Brouwers, J. R. B. J. (2008) · Obstetrical & Gynecological Survey · doi:10.1097/ogx.0b013e3181676be8 · Cited by 37
Broyles, L. M., Colbert, A. M., Tate, J. A., Swigart, V. A., & Happ, M. B. (2008) · Critical Care Medicine · doi:10.1097/01.ccm.0000292010.11345.24 · Cited by 35
NTP‐CERHR Expert Panel Report on the reproductive and developmental toxicity of fluoxetine
Hines, R. N., Adams, J., Louis, G. M. B., Faber, W. D., Holson, J. F., Jacobson, S. W., Keszler, M., McMartin, K. E., Segraves, R. T., Singer, L. T., et al. (2004) · Birth Defects Research Part B Developmental and Reproductive Toxicology · doi:10.1002/bdrb.20014 · Cited by 33
Rominger, A., Cumming, P. D., Brendel, M., Xiong, G., Zach, C., Karch, S., Tatsch, K., Bartenstein, P., la Fougère, C., Koch, W., et al. (2015) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2014.12.010 · Cited by 34
Whitby, D. H., & Smith, K. M. (2005) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.25.3.411.61597 · Cited by 30
Effect of Abrupt Discontinuation of Antidepressants in Critically Ill Hospitalized Adults
Bainum, T. B., Fike, D. S., Mechelay, D., & Haase, K. K. (2017) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1992 · Cited by 28
Drug-Induced Insomnia and Excessive Sleepiness
Gastel, A. V. (2022) · Sleep Medicine Clinics · doi:10.1016/j.jsmc.2022.06.011 · Cited by 29
Silverstein‐Metzler, M. G., Shively, C. A., Clarkson, T. B., Appt, S. E., Carr, J. J., Kritchevsky, S. B., Jones, S. R., & Register, T. C. (2016) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2016.02.012 · Cited by 26
Pearlstein, T. B., Joliat, M. J., Brown, E. B., & Miner, C. M. (2003) · American Journal of Obstetrics and Gynecology · doi:10.1067/mob.2003.207 · Cited by 26
The Use of a Cholinesterase Inhibitor Review Committee in Long-Term Care
Lee, J., Monette, J., Sourial, N., Monette, M., & Bergman, H. (2007) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2007.02.007 · Cited by 26
Psychotropic drugs in pregnancy: a case-control study
Yarış, F., Ulku, C., Kesim, M., Kadıoğlu, M., Unsal, M. A., Dikici, M. F., Kalyoncu, N. İ., & Yariş, E. (2004) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2004.11.020 · Cited by 25
Barriers to achieving treatment goals: A focus on sleep disturbance and sexual dysfunction
Morehouse, R. L., MacQUEEN, G. M., & Kennedy, S. H. (2011) · Journal of Affective Disorders · doi:10.1016/j.jad.2011.03.047 · Cited by 25
Executive Agency for Health and Consumers
Looper, L. (2014) · European Union regulations | European Encyclopedia of law · Cited by 24
Venlafaxine extended release (XR) in the treatment of panic disorder
Kjernisted, K. D., & McIntosh, D. (2007) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.2007.3.1.59 · Cited by 23
Treatments for generalized anxiety disorder
Struzik, L., Vermani, M., Coonerty-Femiano, A., & Katzman, M. A. (2004) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.4.2.285 · Cited by 23
An Open-label Study of Duloxetine for the Treatment of Major Depressive Disorder
Wohlreich, M. M., Martinez, J. M., Mallinckrodt, C. H., Prakash, A., Watkin, J. G., & D, M. F. M. (2005) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000185429.10053.c8 · Cited by 23
Immediate Switching of Antidepressant Therapy: Results from a Clinical Trial of Duloxetine
Wohlreich, M. M., Mallinckrodt, C. H., Watkin, J. G., wilson, M., Greist, J., Delgado, P. L., & D, M. F. M. (2005) · Annals of Clinical Psychiatry · doi:10.1080/10401230500296402 · Cited by 21
The Prescription of Benzodiazepines for Panic Disorder
Nardi, A. E., Cosci, F., Balon, R., Weintraub, S. J., Freire, R. C. R., Krystal, J. H., Roth, T. G., Silberman, E. K., Sonino, N., Fava, G. A., et al. (2018) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000908 · Cited by 20
Raikhel, E., & Garriott, W. (2013) · Duke University Press eBooks · doi:10.1215/9780822395874-001 · Cited by 21
Teixeira, M. Z. (2012) · Cited by 17
Venlafaxine in the treatment of anxiety disorders
Katzman, M. A. (2004) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.4.3.371 · Cited by 18
La, M. K., Thompson Bastin, M. L., Gisewhite, J. T., Johnson, C. A., & Flannery, A. H. (2018) · Journal of Critical Care · doi:10.1016/j.jcrc.2017.07.046 · Cited by 17
Ballanger, B., Bath, K. G., & Mandairon, N. (2019) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2019.06.007 · Cited by 23
Psychiatry’s Continuing Expansion of Depressive Disorder
Wakefield, J. C., & Horwitz, A. V. (2015) · History, philosophy and theory of the life sciences · doi:10.1007/978-94-017-7423-9_12 · Cited by 17
Howard, P. D., Twycross, R., Shuster, J. L., Mihalyo, M., & Wilcock, A. (2012) · Journal of Pain and Symptom Management · doi:10.1016/j.jpainsymman.2012.09.001 · Cited by 21
Antidepressant dosage taken by patients with bipolar disorder: factors associated with irregularity
Bauer, R., Glenn, T., Alda, M., Sagduyu, K., Marsh, W., Grof, P., MUNOZ, R. A., Murray, G., Ritter, P. S., Lewitzka, U., et al. (2013) · International Journal of Bipolar Disorders · doi:10.1186/2194-7511-1-26 · Cited by 16
SSRIs in the Treatment of Depression: A Pharmacological CUL-DE-SAC?
Cowen, P. J. (2023) · Current topics in behavioral neurosciences · doi:10.1007/7854_2023_447 · Cited by 15
Kobayashi, Y., Koshino, Bahk, W.-M., & Sakai (2013) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s48158 · Cited by 6
Understanding antidepressant discontinuation syndrome (ADS) through preclinical experimental models
Zabegalov, K. N., Kolesnikova, T. O., Khatsko, S. L., Volgin, A. D., Yakovlev, O. A., Amstislavskaya, T. G., Alekseeva, P. A., Мешалкина, Д. А., Friend, A. J., Bao, W., et al. (2018) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2018.04.003 · Cited by 15
Guideline for pharmacological treatment of schizophrenia 2022
Japanese Society of Neuropsychopharmacology (2024) · Neuropsychopharmacology Reports · doi:10.1002/npr2.12497 · Cited by 19
Higuchi, T., Hong, J. P., Jung, H., Watanabe, Y., Kunitomi, T., & Kamijima, K. (2011) · Psychiatry and Clinical Neurosciences · doi:10.1111/j.1440-1819.2011.02243.x · Cited by 14
Moclobemide discontinuation syndrome predominantly presenting with influenza-like symptoms
Curtin, F., Berney, P., & Kaufmann, C. (2002) · Journal of Psychopharmacology · doi:10.1177/026988110201600314 · Cited by 14
Characteristics of Escitalopram Discontinuation Syndrome: A Preliminary Study
Yasui-Furukori, N., Hashimoto, K., Tsuchimine, S., Tomita, T., Sugawara, N., Ishioka, M., & Nakamura, K. (2016) · Clinical Neuropharmacology · doi:10.1097/wnf.0000000000000139 · Cited by 13
Recognition and management of antidepressant discontinuation syndrome
Bhat, V., & Kennedy, S. H. (2017) · Journal of Psychiatry and Neuroscience · doi:10.1503/jpn.170022 · Cited by 13
Lovell, A. M. (2013) · Duke University Press eBooks · doi:10.1215/9780822395874-006 · Cited by 13
Metadata
- Authors
- Haddad, P. M.
- Corresponding author
- Haddad, Peter M.
- ORCID
- Haddad, Peter M.
- Venue
- Drug Safety
- Published
- 2001
- Volume
- 24
- Issue
- 3
- Pages
- 183-197
- ISSN
- 0114-5916 (ISSN-L)
- OpenAlex
- W1593032895
- Cited by
- 214
- References
- 99
- Citations by year
- 2026: 7 · 2025: 6 · 2024: 7 · 2023: 5 · 2022: 10 · 2021: 5 · 2020: 5 · 2019: 5 · 2018: 9 · 2017: 8 · 2016: 7 · 2015: 10 · 2014: 7 · 2013: 24 · 2012: 4
- FWCI
- 1.13
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Drug Safety (publishedVersion)
- PubMed (publishedVersion)
- Research Explorer (The University of Manchester) (submittedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
- Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
- Keywords
- antidepressant discontinuation syndrome, antidepressant withdrawal symptoms, selective serotonin reuptake inhibitors, tricyclic antidepressants, monoamine oxidase inhibitors, antidepressant tapering, fluoxetine, venlafaxine, breastfeeding
- MeSH terms
- Animals, Antidepressive Agents, Antidepressive Agents, Tricyclic, Humans, Monoamine Oxidase Inhibitors, Patient Compliance, Substance Withdrawal Syndrome, Syndrome, Selective Serotonin Reuptake Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
